Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05182697Not ApplicableRecruiting

SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Role: lead

NCT03066193Phase 2Completed

Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome

Role: collaborator

NCT03651726Phase 2Unknown

A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome

Role: lead

NCT03646552Phase 2Unknown

A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea

Role: lead

All 4 trials loaded